MBOT · Insider Trading
Microbot Medical, Inc. Common Stock
Every open-market purchase and sale reported by MBOT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-03 | Prattipati Laxminarain | Director | A | +10,000 deriv. | — |
| 2026-04-03 | Aileen Ptucha Stockburger | Director | A | +10,000 deriv. | — |
| 2026-04-03 | Martin J. Madden | Director | A | +10,000 deriv. | — |
| 2026-04-03 | Tal Baruch Wenderow | Director | A | +10,000 deriv. | — |
| 2026-04-03 | David James Wilson | Director | A | +10,000 deriv. | — |
| 2026-04-03 | Scott R Burell | Director | A | +10,000 deriv. | — |
| 2026-02-20 | Harel Gadot | Chairman, President and CEO | A | +480,000 deriv. | — |
| 2026-02-20 | Juan Diaz-Cartelle | Chief Medical Officer | A | +105,000 deriv. | — |
| 2026-02-20 | Rachel Vaknin | Chief Financial Officer | A | +105,000 deriv. | — |
| 2026-02-20 | Simon Sharon | General Manager, CTO | A | +105,000 deriv. | — |
| 2025-02-07 | Simon Sharon | General Manager, CTO | A | +52,500 deriv. | — |
| 2025-02-07 | Harel Gadot | Chairman, President and CEO | A | +240,000 deriv. | — |
| 2025-02-07 | Rachel Vaknin | Chief Financial Officer | A | +52,500 deriv. | — |
| 2025-02-07 | Juan Diaz-Cartelle | Chief Medical Officer | A | +52,500 deriv. | — |
| 2025-01-30 | Scott R Burell | Director | A | +10,000 deriv. | — |
| 2025-01-30 | David James Wilson | Director | A | +20,000 deriv. | — |
| 2025-01-30 | Martin J. Madden | Director | A | +10,000 deriv. | — |
| 2025-01-30 | Tal Baruch Wenderow | Director | A | +10,000 deriv. | — |
| 2025-01-30 | Prattipati Laxminarain | Director | A | +10,000 deriv. | — |
| 2025-01-30 | Aileen Ptucha Stockburger | Director | A | +10,000 deriv. | — |
| 2024-02-26 | Simon Sharon | General Manager, CTO | A | +35,000 deriv. | — |
| 2024-02-26 | Harel Gadot | Chairman, President and CEO | A | +239,567 deriv. | — |
| 2024-02-26 | Juan Diaz-Cartelle | Chief Medical Officer | A | +17,500 deriv. | — |
| 2024-02-26 | Rachel Vaknin | Chief Financial Officer | A | +35,000 deriv. | — |
| 2023-11-06 | Martin J. Madden | Director | A | +74,218 deriv. | — |
| 2023-11-06 | Scott R Burell | Director | A | +74,218 deriv. | — |
| 2023-11-06 | Tal Baruch Wenderow | Director | A | +74,218 deriv. | — |
| 2023-11-06 | Prattipati Laxminarain | Director | A | +74,218 deriv. | — |
| 2023-11-06 | Aileen Ptucha Stockburger | Director | A | +74,218 deriv. | — |
| 2023-11-06 | Yoseph Bornstein | Director | A | +74,218 deriv. | — |
| 2023-08-03 | Simon Sharon | General Manager, CTO | A | +17,500 deriv. | — |
| 2023-08-03 | Harel Gadot | Chairman, President and CEO | A | +80,000 deriv. | — |
| 2023-08-03 | Rachel Vaknin | Chief Financial Officer | A | +17,500 deriv. | — |
| 2023-08-03 | Eyal Morag | Chief Medical Officer | A | +17,500 deriv. | — |
| 2023-01-19 | Simon Sharon | General Manager, CTO | A | +35,000 deriv. | — |
| 2023-01-19 | Eyal Morag | Chief Medical Officer | A | +35,000 deriv. | — |
| 2023-01-09 | Rachel Vaknin | Chief Financial Officer | A | +13,000 deriv. | — |
| 2023-01-09 | Harel Gadot | Chairman, President and CEO | A | +160,000 deriv. | — |
| 2022-09-23 | Prattipati Laxminarain | Director | A | +16,637 deriv. | — |
| 2022-09-23 | Martin J. Madden | Director | A | +16,637 deriv. | — |
| 2022-09-23 | Scott R Burell | Director | A | +16,637 deriv. | — |
| 2022-09-23 | Yoseph Bornstein | Director | A | +16,637 deriv. | — |
| 2022-09-23 | Aileen Ptucha Stockburger | Director | A | +16,637 deriv. | — |
| 2022-09-23 | Tal Baruch Wenderow | Director | A | +16,637 deriv. | — |
| 2022-07-20 | Rachel Vaknin | Chief Financial Officer | A | +10,000 deriv. | — |
| 2022-01-28 | Eyal Morag | Chief Medical Officer | A | +25,000 deriv. | — |
| 2022-01-28 | Simon Sharon | General Manager, CTO | A | +25,000 deriv. | — |
| 2022-01-28 | Harel Gadot | Chairman, President and CEO | A | +100,000 deriv. | — |
| 2021-10-05 | Scott R Burell | Director | A | +13,571 deriv. | — |
| 2021-10-05 | Prattipati Laxminarain | Director | A | +13,571 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Harel Gadot | Chairman, President and CEO | 136,847 | $128.87K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MBOT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.